ADDvise Groups revenue and EBT for Q4 2018 better than anticipated – Regulatory information

25-01-2019   Regulatory press release

ADDvise Group has made a preliminary assessment of the Group revenue and earnings before tax (EBT) for the fourth quarter 2018. Revenue and EBT show strong improvement when compared to the fourth quarter 2017.

Revenue in Q4 2018 is estimated to reach 73 MSEK compared to 62 MSEK in Q4 2017, an increase by over 17 %. Earnings before tax (EBT) in Q4 2018 is estimated to reach 1,4 MSEK compared to -7,4 MSEK in Q4 2017.

-        The EBT is driven by the positive revenue trend combined with the effect from synergies in acquired businesses, says Rikard Akhtarzand in a comment to the preliminary result for Q4.

Revenue for the full year 2018 is estimated to reach 268 MSEK compared to 240 MSEK for the full year 2017, an increase by more than 11 %. Earnings before tax (EBT) is estimated to reach -2,7 MSEK for 2018. EBT for the full year in 2017 reached -10,6 MSEK.

The numbers are preliminary, and the fourth quarter report will be released February 21st 2019.

For further information, please contact:

Rikard Akhtarzand, CEO
+46 765-25 90 71
rikard.akhtarzand@addvisegroup.se 


Important information:
 

This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on January 25th 2019 at 13:15 CET.

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.

Latest press releases

ADDvise announces preliminary result for 2022 which is stronger than expected

Regulatory

The preliminary result for ADDvise Group for the full year 2022 significantly deviates from what ADDvise Group considers to be current market expectations. [image] The net sales pro forma full year 2022 rolling 12 months amounted to SEK 1,097 million with an adjusted EBITDA pro forma of SEK 241 million. The financial targets for the…

ADDvise receives order worth USD 3.5 million

Regulatory

ADDvise Group AB’s subsidiary Poly Pharmaceuticals Inc has received an order from AxisCare Health Logistics Inc, a company distributing equipment and medical supplies to hospitals, clinics, medical offices and medical equipment suppliers. The order is worth approximately USD 3.5 million. The order consists of delivery of the prescription dietary supplemental Folite, developed and manufactured by…

ADDvise receives order worth USD 1.8 million

Regulatory

ADDvise Group AB’s subsidiary MRC Systems FZE has received an order from Nasser Saeed Al Hajri & Partners Contracting (NHS & Partners), a leading construction contractor in the United Arab Emirates. The order is worth approximately USD 1.8 million. The order involves the detailed design, supply and installation of an ISO 8 and ISO 7…